Brandon Van Buren, a director at Cellebrite DI Ltd. (NASDAQ:CLBT), filed a Form 4 on September 17, 2026, disclosing the acquisition of 15,190 restricted share units at no cost, vesting in full one year from the grant date.

Key Highlights

  • Grant date: September 17, 2026, with 15,190 restricted share units (RSUs) acquired at a price of $0.
  • Vesting schedule: All 15,190 RSUs vest on September 17, 2027, according to the filing.
  • RSU structure: Each RSU represents a contingent right to receive one Ordinary Share of Cellebrite DI Ltd. upon settlement.
  • Resulting ownership: Following the transaction, Van Buren beneficially owns 50,744 ordinary shares directly.
  • Security type: Ordinary shares with par value NIS 0.00001 per share.
  • Role: Van Buren is identified as a Director of the issuer in the filing.

Director Van Buren's RSU Award at Cellebrite DI Ltd.

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Brandon Van Buren, a director of Cellebrite DI Ltd. (NASDAQ:CLBT), received an award of 15,190 restricted share units on September 17, 2026. The transaction was recorded under transaction code "A" (acquisition), and the price paid was $0, consistent with a standard equity compensation grant rather than an open-market purchase.

The filing states that the RSUs "will vest on September 17, 2027," meaning the grant carries a one-year cliff vesting schedule. Each RSU, as explained in the filing's footnote, "represents a contingent right to receive one Ordinary Share of the Issuer upon settlement." The underlying security is Cellebrite's ordinary shares, which carry a par value of NIS 0.00001 per share.

Following this reported transaction, Van Buren's direct beneficial ownership stands at 50,744 ordinary shares, as reported in the filing. No derivative securities were reported in Table II, and the form was filed by Van Buren as a single reporting person. Van Buren's address of record is listed as Petah Tikva, Israel. The form bears his signature dated September 17, 2026.

What Was Disclosed

The filing discloses an RSU grant of 15,190 shares to Cellebrite director Brandon Van Buren on September 17, 2026, at no cost, vesting one year later, bringing his total direct beneficial ownership to 50,744 ordinary shares.